Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases

Pham et al., Rheumatology Advances in Practice, doi:10.1093/rap/rkab014
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 20% Improvement Relative Risk ICU admission -35% HCQ for COVID-19  Pham et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 42 patients in the USA Study underpowered to detect differences c19hcq.org Pham et al., Rheumatology Advances in .., Mar 2021 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Tiny retrospective database analysis of hospitalized COVID-19 patients with rheumatologic disease containing 14 chronic HCQ and 28 control patients. Patients are very poorly matched. Bias against HCQ is clear in the abstract which mentions differences favoring HCQ but ignores those favoring control (large differences in ethnicity, rheumatic conditions, hypertension, coronary artery disease, solid organ transplant recipients, immunosuppresive drugs). 61% of control patients also received HCQ. Adherence for chronic HCQ patients was not examined. Despite the very large differences between the groups, no adjustments are made. The study claims that HCQ did not prevent severe cases, but the study is among hospitalized patients, i.e., they already have cases severe enough for hospitalization - this study can not identify a protective effect of HCQ that reduces the probability of disease severe enough for hospitalization.
Although the 20% lower mortality is not statistically significant, it is consistent with the significant 26% lower mortality [22‑30%] from meta analysis of the 249 mortality results to date.
risk of death, 19.7% lower, RR 0.80, p = 0.77, treatment 2 of 14 (14.3%), control 5 of 28 (17.9%), NNT 28, odds ratio converted to relative risk, univariate.
risk of ICU admission, 35.5% higher, RR 1.35, p = 0.61, treatment 4 of 14 (28.6%), control 6 of 28 (21.4%), odds ratio converted to relative risk, univariate.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pham et al., 2 Mar 2021, retrospective, USA, peer-reviewed, 5 authors.
This PaperHCQAll
Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
Khanh Pham, Heidi Torres, Michael J Satlin, Parag Goyal, Roy M Gulick
Rheumatology Advances in Practice, doi:10.1093/rap/rkab014
Objective To compare baseline characteristics, clinical presentations and outcomes of patients with rheumatic conditions requiring hospitalization for coronavirus disease 2019 (COVID-19) who received chronic HCQ with those who did not receive chronic HCQ. Methods We identified all patients with a rheumatologic disease who were admitted with COVID-19 to two hospitals in New York City between 3 March 3 and 30 April 2020. Patients who received chronic HCQ prior to admission were matched 1:2 (610 years of age) with patients who did not receive chronic HCQ. We compared demographics, comorbidities, HCQ dosages, concurrent medications, presentations and outcomes between the groups. Results There were 14 patients receiving HCQ and 28 matched control subjects. The median age of cases was 63 years [interquartile range (IQR) 43-73) and 60 years (IQR 41-75) for controls. Control subjects had a higher prevalence of pulmonary diseases (42.8%), diabetes (35.7%) and obesity (35.7%) than their case counterparts (28.6%, 14.3% and 7.1%, respectively). A higher proportion of cases than control subjects (50% vs 25%) reported the use of prednisone for their rheumatic conditions prior to admission. Despite these differences in baseline characteristics, univariate logistic regression revealed no statistically significant differences in the need for mechanical ventilation [OR 1.5 (95% CI 0.34, 6.38)] or in-hospital mortality [OR 0.77 (95% CI 0.13, 4.56)]. Conclusion HCQ therapy in individuals with rheumatic conditions was not associated with less severe presentations of COVID-19 among hospitalized patients compared with individuals with rheumatic conditions not receiving HCQ.
References
Abella, Jolkovsky, Biney, Efficacy and safety of hydroxychloroquine vs placebo for preexposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial, JAMA Intern Med
Adamou, Aljayyousi, Alshak ; Bryan, Ang, Beideck et al., including the Clinical and Translational Science Center (UL1 TR000457) and Joint Clinical Trials Office, as well as the Weill Cornell T32 training grant
Baden, Sahly, Essink, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N Engl J Med
Carbillon, Benbara, Boujenah, Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217847
Cavalcanti, Zampieri, Rosa, Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19, N Engl J Med
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Gianfrancesco, Hyrich, Al-Adely, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis
Goyal, Choi, Pinheiro, Clinical characteristics of Covid-19 in New York City, N Engl J Med
Haberman, Axelrad, Covid-19 in immune-mediated inflammatory diseases-case series from New York, N Engl J Med
Horby, Mafham, Linsell, Effect of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Mitja, Corbacho-Monne, Ubals, Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial, Clin Infect Dis, doi:10.1093/cid/ciaa1009
Pham, None
Rentsch, Devito, Mackenna, Effect of preexposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform, Lancet Rheumatol
Self, Semler, Leither, Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial, JAMA
Singer, Kaelber, Antonelli, Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218500
Tang, Cao, Han, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ
Ulrich, Troxel, Carmody, Treating COVID-19 with hydroxychloroquine (TEACH): a multicenter, double-blind randomized controlled trial in hospitalized patients, Open Forum Infect Dis
Wu, Chen, Cai, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med
Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Zhong, Shen, Yang, COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study, Lancet Rheumatol
{ 'indexed': {'date-parts': [[2023, 3, 20]], 'date-time': '2023-03-20T00:08:54Z', 'timestamp': 1679270934762}, 'reference-count': 20, 'publisher': 'Oxford University Press (OUP)', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2021, 3, 2]], 'date-time': '2021-03-02T00:00:00Z', 'timestamp': 1614643200000}, 'content-version': 'vor', 'delay-in-days': 60, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 1, 25]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Objective</jats:title>\n' ' <jats:p>To compare baseline characteristics, clinical presentations and ' 'outcomes of patients with rheumatic conditions requiring hospitalization for coronavirus ' 'disease 2019 (COVID-19) who received chronic HCQ with those who did not receive chronic ' 'HCQ.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>We identified all patients with a rheumatologic disease who were ' 'admitted with COVID-19 to two hospitals in New York City between 3 March 3 and 30 April 2020. ' 'Patients who received chronic HCQ prior to admission were matched 1:2 (±10\u2009years of age) ' 'with patients who did not receive chronic HCQ. We compared demographics, comorbidities, HCQ ' 'dosages, concurrent medications, presentations and outcomes between the groups.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>There were 14 patients receiving HCQ and 28 matched control ' 'subjects. The median age of cases was 63\u2009years [interquartile range (IQR) 43–73) and ' '60\u2009years (IQR 41–75) for controls. Control subjects had a higher prevalence of pulmonary ' 'diseases (42.8%), diabetes (35.7%) and obesity (35.7%) than their case counterparts (28.6%, ' '14.3% and 7.1%, respectively). A higher proportion of cases than control subjects (50% vs ' '25%) reported the use of prednisone for their rheumatic conditions prior to admission. ' 'Despite these differences in baseline characteristics, univariate logistic regression ' 'revealed no statistically significant differences in the need for mechanical ventilation [OR ' '1.5 (95% CI 0.34, 6.38)] or in-hospital mortality [OR 0.77 (95% CI 0.13, 4.56)].</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>HCQ therapy in individuals with rheumatic conditions was not ' 'associated with less severe presentations of COVID-19 among hospitalized patients compared ' 'with individuals with rheumatic conditions not receiving HCQ.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/rap/rkab014', 'type': 'journal-article', 'created': {'date-parts': [[2021, 3, 7]], 'date-time': '2021-03-07T04:06:58Z', 'timestamp': 1615090018000}, 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients ' 'with rheumatic diseases', 'prefix': '10.1093', 'volume': '5', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-7446-3177', 'authenticated-orcid': False, 'given': 'Khanh', 'family': 'Pham', 'sequence': 'first', 'affiliation': [{'name': 'NewYork-Presbyterian Hospital, Weill Cornell Medical Center'}]}, { 'given': 'Heidi', 'family': 'Torres', 'sequence': 'additional', 'affiliation': [{'name': 'NewYork-Presbyterian Hospital, Weill Cornell Medical Center'}]}, { 'given': 'Michael J', 'family': 'Satlin', 'sequence': 'additional', 'affiliation': [ {'name': 'NewYork-Presbyterian Hospital, Weill Cornell Medical Center'}, { 'name': 'Department of Medicine, Weill Cornell Medicine, New York, NY, ' 'USA'}]}, { 'given': 'Parag', 'family': 'Goyal', 'sequence': 'additional', 'affiliation': [ {'name': 'NewYork-Presbyterian Hospital, Weill Cornell Medical Center'}, { 'name': 'Department of Medicine, Weill Cornell Medicine, New York, NY, ' 'USA'}]}, { 'given': 'Roy M', 'family': 'Gulick', 'sequence': 'additional', 'affiliation': [ {'name': 'NewYork-Presbyterian Hospital, Weill Cornell Medical Center'}, { 'name': 'Department of Medicine, Weill Cornell Medicine, New York, NY, ' 'USA'}]}], 'member': '286', 'published-online': {'date-parts': [[2021, 3, 2]]}, 'reference': [ {'key': '2021041412234753600_rkab014-B1', 'author': 'World Health Organization'}, { 'key': '2021041412234753600_rkab014-B2', 'doi-asserted-by': 'crossref', 'first-page': '533', 'DOI': '10.1016/S1473-3099(20)30120-1', 'article-title': 'An interactive web-based dashboard to track COVID-19 in real time', 'volume': '20', 'author': 'Dong', 'year': '2020', 'journal-title': 'Lancet Infect Dis'}, { 'key': '2021041412234753600_rkab014-B3', 'doi-asserted-by': 'crossref', 'first-page': '934', 'DOI': '10.1001/jamainternmed.2020.0994', 'article-title': 'Risk factors associated with acute respiratory distress syndrome and ' 'death in patients with coronavirus disease 2019 pneumonia in Wuhan, ' 'China', 'volume': '180', 'author': 'Wu', 'year': '2020', 'journal-title': 'JAMA Intern Med'}, { 'key': '2021041412234753600_rkab014-B4', 'doi-asserted-by': 'crossref', 'first-page': '2372', 'DOI': '10.1056/NEJMc2010419', 'article-title': 'Clinical characteristics of Covid-19 in New York City', 'volume': '382', 'author': 'Goyal', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '2021041412234753600_rkab014-B5', 'doi-asserted-by': 'crossref', 'first-page': '403', 'DOI': '10.1056/NEJMoa2035389', 'article-title': 'Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine', 'volume': '384', 'author': 'Baden', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '2021041412234753600_rkab014-B6', 'doi-asserted-by': 'crossref', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2)', 'volume': '71', 'author': 'Yao', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': '2021041412234753600_rkab014-B7', 'doi-asserted-by': 'crossref', 'first-page': '16', 'DOI': '10.1038/s41421-020-0156-0', 'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is ' 'effective in inhibiting SARS-CoV-2 infection in vitro', 'volume': '6', 'author': 'Liu', 'year': '2020', 'journal-title': 'Cell Discov'}, { 'key': '2021041412234753600_rkab014-B8', 'doi-asserted-by': 'crossref', 'first-page': 'ofaa446', 'DOI': '10.1093/ofid/ofaa446', 'article-title': 'Treating COVID-19 with hydroxychloroquine (TEACH): a multicenter, ' 'double-blind randomized controlled trial in hospitalized patients', 'volume': '7', 'author': 'Ulrich', 'year': '2020', 'journal-title': 'Open Forum Infect Dis'}, { 'key': '2021041412234753600_rkab014-B9', 'article-title': 'Hydroxychloroquine for early treatment of adults with mild Covid-19: a ' 'randomized-controlled trial', 'author': 'Mitjà', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': '2021041412234753600_rkab014-B10', 'doi-asserted-by': 'crossref', 'first-page': '2165', 'DOI': '10.1001/jama.2020.22240', 'article-title': 'Effect of hydroxychloroquine on clinical status at 14 days in ' 'hospitalized patients with COVID-19: a randomized clinical trial', 'volume': '324', 'author': 'Self', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '2021041412234753600_rkab014-B11', 'doi-asserted-by': 'crossref', 'first-page': '2041', 'DOI': '10.1056/NEJMoa2019014', 'article-title': 'Hydroxychloroquine with or without azithromycin in mild-to-moderate ' 'Covid-19', 'volume': '383', 'author': 'Cavalcanti', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '2021041412234753600_rkab014-B12', 'doi-asserted-by': 'crossref', 'first-page': 'm1849', 'DOI': '10.1136/bmj.m1849', 'article-title': 'Hydroxychloroquine in patients with mainly mild to moderate coronavirus ' 'disease 2019: open label, randomised controlled trial', 'volume': '369', 'author': 'Tang', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '2021041412234753600_rkab014-B13', 'doi-asserted-by': 'crossref', 'first-page': '2030', 'DOI': '10.1056/NEJMoa2022926', 'article-title': 'Effect of hydroxychloroquine in hospitalized patients with Covid-19', 'volume': '383', 'author': 'Horby', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '2021041412234753600_rkab014-B14', 'doi-asserted-by': 'crossref', 'first-page': '195', 'DOI': '10.1001/jamainternmed.2020.6319', 'article-title': 'Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure ' 'SARS-CoV-2 prophylaxis among health care workers: a randomized clinical ' 'trial', 'volume': '181', 'author': 'Abella', 'year': '2020', 'journal-title': 'JAMA Intern Med'}, { 'key': '2021041412234753600_rkab014-B15', 'doi-asserted-by': 'crossref', 'first-page': 'e19–27', 'DOI': '10.1016/S2665-9913(20)30378-7', 'article-title': 'Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: ' 'a population-based cohort study in patients with rheumatoid arthritis ' 'or systemic lupus erythematosus using the OpenSAFELY platform', 'volume': '3', 'author': 'Rentsch', 'year': '2021', 'journal-title': 'Lancet Rheumatol'}, { 'key': '2021041412234753600_rkab014-B16', 'article-title': 'Clinical course of COVID-19 in patients with systemic lupus ' 'erythematosus under long-term treatment with hydroxychloroquine', 'author': 'Carbillon', 'year': '2020', 'journal-title': 'Ann Rheum Dis'}, { 'key': '2021041412234753600_rkab014-B17', 'doi-asserted-by': 'crossref', 'DOI': '10.1136/annrheumdis-2020-218500', 'article-title': 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and ' 'rheumatoid arthritis', 'author': 'Singer', 'year': '2020', 'journal-title': 'Ann Rheum Dis'}, { 'key': '2021041412234753600_rkab014-B18', 'doi-asserted-by': 'crossref', 'first-page': '85', 'DOI': '10.1056/NEJMc2009567', 'article-title': 'Covid-19 in immune-mediated inflammatory diseases—case series from New ' 'York', 'volume': '383', 'author': 'Haberman', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '2021041412234753600_rkab014-B19', 'doi-asserted-by': 'crossref', 'first-page': '859', 'DOI': '10.1136/annrheumdis-2020-217871', 'article-title': 'Characteristics associated with hospitalisation for COVID-19 in people ' 'with rheumatic disease: data from the COVID-19 Global Rheumatology ' 'Alliance physician-reported registry', 'volume': '79', 'author': 'Gianfrancesco', 'year': '2020', 'journal-title': 'Ann Rheum Dis'}, { 'key': '2021041412234753600_rkab014-B20', 'doi-asserted-by': 'crossref', 'first-page': 'e557–64', 'DOI': '10.1016/S2665-9913(20)30227-7', 'article-title': 'COVID-19 in patients with rheumatic disease in Hubei province, China: a ' 'multicentre retrospective observational study', 'volume': '2', 'author': 'Zhong', 'year': '2020', 'journal-title': 'Lancet Rheumatol'}], 'container-title': 'Rheumatology Advances in Practice', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://academic.oup.com/rheumap/advance-article-pdf/doi/10.1093/rap/rkab014/36433820/rkab014.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/rheumap/article-pdf/5/1/rkab014/37058820/rkab014.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/rheumap/article-pdf/5/1/rkab014/37058820/rkab014.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 4, 16]], 'date-time': '2021-04-16T15:59:49Z', 'timestamp': 1618588789000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/rheumap/article/doi/10.1093/rap/rkab014/6156645'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021]]}, 'references-count': 20, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2021, 1, 25]]}}, 'URL': 'http://dx.doi.org/10.1093/rap/rkab014', 'relation': {}, 'ISSN': ['2514-1775'], 'subject': [], 'published-other': {'date-parts': [[2021]]}, 'published': {'date-parts': [[2021]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit